RecruitingPhase 4NCT07376889

Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

COMBAT-SAB: Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

Sponsor

Intermountain Health Care, Inc.

Enrollment

2,096 participants

Start Date

Feb 1, 2026

Study Type

INTERVENTIONAL

Conditions

Staphylococcus Aureus Bacteremia

Summary

The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which are positive for a certain type of bacteria.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB), a drug called Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), and others for people with staphylococcus aureus bacteremia. The study is currently recruiting participants at 13 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAntibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)

Intravenous anti-staphylococcal beta-lactam, either cefazolin or nafcillin, per the discretion of the treating physician.

DRUGAntibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)

Vancomycin or daptomycin, per discretion of the treating physician

DRUGCombination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)

Patients with methicillin-sensitive S. aureus bacteremia (MSSAB) and no contraindications will receive an anti-staphylococcal beta-lactam, either cefazolin or nafcillin, plus ertapenem

DRUGCombination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)

Daptomycin plus ceftaroline

Locations(13)

Platte Valley Hospital

Brighton, Colorado, United States

Saint Joseph Hospital

Denver, Colorado, United States

St. Mary's Regional Hospital

Grand Junction, Colorado, United States

Good Samaritan Hospital

Lafayette, Colorado, United States

Lutheran Medical Center

Wheat Ridge, Colorado, United States

St. Vincent Regional Hospital

Billings, Montana, United States

St. James Hospital

Butte, Montana, United States

Holy Rosary Hospital

Miles City, Montana, United States

Intermountain Medical Center

Murray, Utah, United States

McKay-Dee Hospital

Ogden, Utah, United States

Utah Valley Hospital

Provo, Utah, United States

LDS Hospital

Salt Lake City, Utah, United States

St. George Regional Hospital

St. George, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07376889

Related Trials

Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

NCT0663733219 locations

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

NCT048862846 locations